Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP) data

The RSV-MIPP has 2 components – a recombinant RSV pre-fusion F vaccine (commonly known by its trade name Abrysvo), provided under the National Immunisation Program (NIP), and the long-acting RSV monoclonal antibody nirsevimab (Beyfortus), provided through state and territory programs.

The vaccine component of the program commenced on 3 February 2025 and provides Medicare-registered pregnant women across Australia with free access to Abrysvo under the NIP. 

A single dose of Abrysvo is recommended for pregnant women from 28 weeks gestation and provides protection for their infant against severe RSV disease. Administration prior to 36 weeks gestation is encouraged because, if the infant is born within 2 weeks of the mother receiving the vaccine, there is insufficient time for the immune response to develop.

In addition to the vaccination program for pregnant women, nirsevimab is available for free to eligible infants under varying state/territory funded infant programs. It is recommended for infants: 

• whose mothers did not receive a dose of Abrysvo during pregnancy
• who were born within two weeks of the mother receiving Abrysvo
• who are at increased risk of severe RSV disease, regardless of maternal vaccination status. 

Nirsevimab is also recommended for children up to 24 months of age entering their second RSV season who are at risk of severe RSV disease.

Click on the tiles below to explore the RSV immunisation uptake data in the first full year of the program.

Maternal RSV vaccine uptake data

Early childhood RSV monoclonal antibody uptake data